Catherine Carter, APRN
Family · Tooele, UTNPI 1245510627
Payments from drug & device makers
Across 114 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$355
- Novo Nordisk$262
- Axsome Therapeutics, Inc.$215
- Lilly USA, LLC$212
- AstraZeneca$178
- Mylan Specialty L.p.$172
- plus $737 from 20 others
What the payments were for
- Food & beverage$2,01595%
- Education$1165%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 17 | $355 |
| Novo Nordisk | 12 | $262 |
| Axsome Therapeutics, Inc. | 11 | $215 |
| Lilly USA, LLC | 14 | $212 |
| AstraZeneca | 12 | $178 |
| Mylan Specialty L.p. | 8 | $172 |
| Boehringer Ingelheim | 4 | $99 |
| Pfizer | 6 | $91 |
| Abbott | 4 | $81 |
| Viatris Specialty LLC | 3 | $65 |
| Otsuka America Pharmaceutical, Inc. | 3 | $65 |
| Astellas Pharma US Inc | 2 | $41 |
| Boston Scientific | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Bausch Health US, LLC | 2 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $29 |
| Lundbeck LLC | 1 | $21 |
| Novartis | 1 | $20 |
| Medtronic | 1 | $18 |
| Antares Pharma, Inc. | 1 | $15 |
| Amgen | 1 | $14 |
| Exact Sciences | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$116
How this compares
$2,131 in reported general payments places this provider in the 80th percentile of 1,460 family providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 65 | $81,810 |
| TrulicityDulaglutide | 39 | $39,049 |
| FarxigaDapagliflozin Propanediol | 43 | $37,279 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $31,224 |
| EliquisApixaban | 29 | $28,549 |
| JardianceEmpagliflozin | 30 | $28,113 |
| MounjaroTirzepatide | 22 | $28,102 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 19 | $13,010 |
| XareltoRivaroxaban | 13 | $11,610 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $11,504 |
| Atorvastatin Calcium | 338 | $3,228 |
| Omeprazole | 185 | $3,023 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $2,618 |
| Bupropion XlBupropion Hcl | 87 | $2,437 |
| Duloxetine Hcl | 86 | $2,436 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $262 | $81,81065 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $212 | $67,15261 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $178 | $50,28962 claims |
| PfizerEliquis, Paxlovid | $91 | $29,97842 claims |
| Boehringer IngelheimJardiance | $99 | $28,11330 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,460 family providers in Utah.
Other family in Tooele
- Riley WorthSandy$1.1M
- Katrina BawdenSalt Lake City$446K
- Cortnee RomanSalt Lake City$374K
- Jared ThorleySalt Lake City$368K
- Stephanie GodfreyLindon$358K
- Mary SteinbackSalt Lake City$189K
- Shannon FordSouth Jordan$186K
- Jennalyn MayeuxSalt Lake City$151K
- Brett RawlinsKaysville$149K
- Shelby MillerSandy$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.